טוען...
Neoadjuvant oncogene-targeted therapy in early stage non-small cell lung cancer as a strategy to improve clinical outcome and identify early mechanisms of resistance
Evaluations of resistance mechanisms to targeted treatments in non-small cell lung cancer (NSCLC) are necessary for development of improved treatment after progression and to help delay progression. Populations of cells that survive after initial treatment form the basis of resistance via outgrowth...
שמור ב:
| הוצא לאור ב: | Clin Lung Cancer |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5378381/ https://ncbi.nlm.nih.gov/pubmed/27378174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2016.05.025 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|